Philadelphia, PA, United States of America

Wafik S El-Deiry

This inventor holds 26 USPTO granted patents and 25 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Cancer Therapeutics. Top assignees: Institute for Cancer Research, The Penn State Research Foundation, Johns Hopkins University. Active years: 1998-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wafik S El-Deiry. Retrieved from https://idiyas.com/inventor/wafik-s-el-deiry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 25)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 60(Granted Patents)

Location History:

Philadelphia, PA (US) (1998 - 2024)
Bryn Mawr, PA (US) (2014 - 2024)

Company Filing History:

13 out of 69

Institute for Cancer Research

patents

9 out of 1,340

The Penn State Research Foundation

patents

2 out of 3,801

Johns Hopkins University

patents

4. 1 out of 2

Institute for Cancer Research D/B/A the Research Institute of Fox Chase Cancer Center

patents

5. 1 out of 2,659

University of Pennsylvania

patents

Years Active: 1998-2026

Loading Chart...

Areas of Expertise:

Tumor Treatment

miRNA Targeting

CDK Inhibition

HSP90

Cancer Cell Growth

TRAIL Pathway

Prodigiosin

DNA Damage Response

p53 Signaling

Colorectal Cancer

Small Molecule Induction

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595483 - TREATMENT OF TUMORS WITH MIRNA TARGETING CDK4/CDK6 (2026-04-07),

2. 12344599 - Prodigiosin analogs and methods of use (2025-07-01),

3. 12098428 - Frequent EGFR and NTRK somatic mutations in colorectal cancer (CRC) with microsatellite instability (MSI) (2024-09-24),

4. 12071622 - miR-3132 upregulation of the trail pathway and apoptotic activity in cancer cells (2024-08-27),

5. 12036223 - Small molecule trail gene induction by normal and tumor cells as an anticancer therapy (2024-07-16),

6. 11993589 - Prodigiosin analogs and methods of use (2024-05-28),

7. 11859183 - Treatment of tumors with miRNA targeting CDK4/CDK6 (2024-01-02),

8. 11578324 - miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cells (2023-02-14),

9. 11535608 - Prodigiosin analogs and methods of use (2022-12-27),

10. 11203598 - Compounds for repressing cancer cell growth (2021-12-21),

11. 11034959 - Treatment of tumors with miRNA targeting CDK4/CDK6 (2021-06-15),

12. 10987356 - Dual inhibition of CDK and HSP90 destabilize H1F1 α and synergistically induces cancer cell death (2021-04-27),

13. 10870640 - Prodigiosin analogs and methods of use (2020-12-22),

14. 10744133 - Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signaling (2020-08-18),

15. 10729692 - Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death (2020-08-04),

Title: Wafik S El-Deiry: Innovator in Cancer Research

Introduction: Wafik S El-Deiry is a prominent figure in the field of cancer research located in Philadelphia, PA. With 22 patents to his name, he has made significant contributions to understanding and treating various cancers, focusing particularly on mechanisms involving EGFR-related and NTRK-related cancers.

Latest Patents: Among his latest patents are groundbreaking methodologies for identifying subjects with cancer that may be susceptible to specific therapeutic agents. One notable patent discusses frequent EGFR and NTRK somatic mutations in colorectal cancer with microsatellite instability. This patent outlines methods geared towards recognizing patients who could benefit from targeted treatments. Another significant patent involves the upregulation of the miR-3132 in the TRAIL pathway, which enhances apoptotic activity in cancer cells. This innovation proposes compositions that utilize miR-3132 alongside pharmaceutical agents to activate the TRAIL signaling pathway as a means of cancer treatment.

Career Highlights: Throughout his career, Wafik S El-Deiry has collaborated with leading research institutions, including the Institute for Cancer Research and the Penn State Research Foundation. His work has not only advanced the scientific understanding of cancer but has also facilitated the development of novel treatment modalities.

Collaborations: El-Deiry has worked alongside esteemed colleagues such as Gen Sheng Wu and Joshua E Allen. These collaborations have played a crucial role in driving forward their shared mission of improving cancer therapies and patient outcomes.

Conclusion: Wafik S El-Deiry continues to be a pivotal force in cancer research through his innovative patents and collaborative work with other experts in the field. His efforts in identifying susceptibility to cancer treatments remain vital for the advancement of personalized medicine in oncology.

Profile summary based on public USPTO records.